Sorafenib, a systemic therapy for hepatocellular carcinoma

Related Experiment Video

Updated: Jul 6, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Nahum Méndez-Sánchez1, Francisco Vásquez-Fernández, Daniel Zamora-Valdés

  • 1Liver Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico. nmendez@medicasur.org.mx

Annals of Hepatology
|April 1, 2008
PubMed

Insights

Hepatocellular carcinoma (HCC) management is complex. The RAS/RAF/MEK/ERK pathway is key in HCC, and sorafenib shows promise for advanced cases.

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Molecular signaling pathways in oncology
  • Pharmacological treatments for liver cancer

Background:

  • Hepatocellular carcinoma (HCC) is a fatal malignancy with limited treatment options.
  • Surgical resection offers the best survival but is only feasible for a small subset of patients.
  • Effective systemic therapies for advanced HCC have been lacking until recently.

Purpose of the Study:

  • To review the role of the RAS/RAF/MEK/ERK signaling pathway in HCC pathogenesis.
  • To discuss the therapeutic potential of sorafenib in advanced HCC.

Main Methods:

  • Literature review focusing on the RAS/RAF/MEK/ERK pathway.
  • Analysis of clinical data regarding sorafenib efficacy in advanced HCC.

Main Results:

  • The RAS/RAF/MEK/ERK signaling pathway is implicated in the development and progression of HCC.
  • Sorafenib demonstrates promising results as a systemic therapy for advanced HCC.

Conclusions:

  • Targeting the RAS/RAF/MEK/ERK pathway represents a viable strategy for HCC treatment.
  • Sorafenib offers a new therapeutic option for patients with advanced hepatocellular carcinoma.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...